11 completed, 4 unknown, 1 not yet recruiting, 1 terminated. 17 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 11, Unknown 4, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 56 | 2026-12-01 | 2026-09-17 |
| COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) AS03, BNT162b2, BNT162b2 (B.1.1.529) - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1270 | 2022-03-30 | 2025-10-20 |
| The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 340 | 2021-11-30 | 2022-07-25 |
| Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years BNT162b2 - SARS-CoV-2 Infection, COVID19 | Phase 2 | Completed | BioNTech SE | 124 | 2021-10-15 | 2024-10-09 |
| Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7) - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | BioNTech SE | 1380 | 2021-08-25 | 2024-11-22 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects BNT162b2s01, BNT162b2 - COVID-19, SARS-CoV-2 Infection | Phase 2 | Completed | BioNTech SE | 137 | 2021-07-26 | 2024-09-19 |
| Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster Placebo, Inactivated vaccine booster, mRNA vaccine booster - Covid19 | Phase 2 | Unknown | Universidad del Desarrollo | 534 | 2021-07-08 | 2021-08-05 |
| Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients Ad26COVS1, ChAdOx1 SARS2 Vaccine, BNT162B2 - COVID-19 | Phase 2 | Unknown | Medical University of Vienna | 200 | 2021-06-15 | 2022-04-20 |
| Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant] - COVID-19 | Phase 2 | Completed | Canadian Immunization Research Network | 669 | 2021-06-11 | 2026-11-10 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19 | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 867 | 2021-05-28 | 2025-04-20 |
| Covid-19 Vaccination in Adolescents and Children Tozinameran, CoronaVac, CoronaVac, intradermal - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 1018 | 2021-05-08 | 2024-01-16 |
| COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo - SARS-CoV Infection, COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 746 | 2021-04-07 | 2025-08-12 |
| To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 726 | 2021-02-16 | 2024-12-06 |
| Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population BNT162b2, Placebo - SARS-CoV-2 | Phase 2 | Completed | BioNTech SE | 960 | 2020-12-04 | 2026-03-20 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals BNT162b1, BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 46969 | 2020-04-29 | 2026-03-25 |
| A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults BNT162a1, BNT162b1, BNT162b2 - Infections, Respiratory, Virus Diseases | Phase 1 / Phase 2 | Completed | BioNTech SE | 512 | 2020-04-23 | 2024-07-12 |
COVID-19 (16) · Severe Acute Respiratory Syndrome (4) · Coronavirus Infections (3) · RNA Virus Infections (2) · Respiratory Tract Infections (2) · Virus Diseases (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Breakthrough Infections (1) · Dermatomyositis (1) · Disease (1) · Hypersensitivity (1) · Lupus Erythematosus, Systemic (1) · Mastocytosis (1)
BioNTech SE (7) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Canadian Immunization Research Network (1) · Chang Gung Memorial Hospital (1) · Fred Hutchinson Cancer Center (1) · Medical University of Vienna (1) · The University of Hong Kong (1) · Universidad del Desarrollo (1)
United States (9) · Germany (5) · Brazil (3) · South Africa (3) · China (2) · Turkey (Türkiye) (2) · Argentina (1) · Austria (1) · Canada (1) · Chile (1) · Mexico (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Amit Bar-Or, MD, FRCP (1) · Cheng-Hsun Chiu, MD, PhD (1) · Dinesh Khanna, MBBS, MSc (1) · James R. Baker Jr., MD (1) · Joanne Langley (1) · Joshua Hill, MD (1) · Judith A. James, MD, PhD (1) · Kirsten E Lyke, M.D. (1) · Meggan C. Mackay, MD, MS (1) · N. Franklin Atkinson Jr., MD (1) · Natasha Mckerran Ruth, MD (1) · Rebecca S. Gruchalla, MD, PhD (1) · Robert L Atmar, M.D. (1)
PMID 39197299, PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34525277, PMID 35081293, PMID 35131133, PMID 35316227, PMID 35472295, PMID 35473709, PMID 35653438, PMID 35739094, PMID 35764637, PMID 35792746, PMID 35798000, PMID 35898343, PMID 36055877, PMID 36120090, PMID 36125366, PMID 36378074, PMID 36399969, PMID 37205592, PMID 37433788, PMID 37527039, PMID 37640860, PMID 37992183, PMID 38012751, PMID 39097927, PMID 39325506, PMID 40237463, PMID 40298376, PMID 40396505, PMID 40930044, PMID 41289027, PMID 41698311
5UM1AI148684-02 (1), 5UM1AI148684-03 (1)